Pulmonology

Results from "real word" asthma treatment with omalizumab correspond to clinical trial findings and suggest that FeNO values can help predict treatment response.

The combination is the first once-daily therapy approved in the US that combines 3 active molecules in a single inhaler.

The marker could serve in treatment trials in lieu of participants prone to exacerbation and the accompanying morbidity and risk of death.

Bronchial thermoplasty was found comparable to omalizumab in an indirect comparison of their effectiveness for uncontrolled, severe asthma.

Produced by GlaxoSmithKline, 100 mg mepolizumab used in conjunction with maximal guideline-recommended therapy, showed a consistent 18% to 20% reduction.

The single-dose inhaler was the first of its kind to get positive recommendation from EMA's Committee for Medicinal Products for Human Use.

The FDA approved the inhaler treatment based on 2 Phase III-B studies running 6 months and 12 months, respectively, to compare the drug’s efficacy in COPD exacerbation care.

Inhaled corticosteroid for wheezing in early childhood is effective in selected patients but does not prevent progression to asthma.

About one million US adults and adolescents live with uncontrolled, persistent asthma — despite there already being an intensive regimen of standard therapies. Dupilumab may be a missing piece to comprehensive treatment.

The CHAMPS study demonstrated that comprehensive asthma interventions proven efficacious in controlled trial settings can be effectively implemented in diverse communities.

The approval marks the first FDA-approved treatment for pulmonary arterial hypertension.

Are asthma patients being mismanaged when treatment guidelines on specialist referrals are overlooked?

ALIS reduced the evidence of nontuberculous mycobacterial lung disease by 29% compared to 9% with guideline-based therapy alone.

Preschool children presenting to emergency departments for wheezing did not benefit from the addition of azithromycin to symptomatic treatment.

A 10-year follow-up of patients with severe asthma finds persistent illness remains difficult to treat.

COPD-related deaths increased 11.6% since 1990, and cases increased 44.2% to 174.5 million.

A new meta-analysis finds that better patient instruction can improve use and effectiveness of hand-held inhalers, and recommends closer scrutiny of how inhalers are mishandled.

A new estimate of the cost of corticosteroid-related morbidity has pulmonologists paying closer attention to steroid-sparing asthma treatments.

The drug reduced exacerbations and improved quality of life for patients who had symptoms despite treatment with corticosteroids and long-acting bronchodilators.

They suffer higher rates of morbidity and mortality from asthma, but their response to treatment and underlying physiological conditions are not as well known.

The proposed once-daily nebulized bronchodilator for COPD returned reports of generally positive toleration, with no new safety issues, in a study of 1,055 patients.

Vertex Pharma’s new Phase 1 and 2 data could help patients with F508del/Min mutations – a severe and difficult-to-treat form of Cystic Fibrosis.

Investigators note that seasonal variation in relapse in MS has been observed, suggesting that season-dependent factors such as ambient air pollution may be involved.

The treatment was tested in a trial of 7,513 patients hospitalized and susceptible to the condition.

The subcutaneous treatment can be used for HAE attacks at home.

The FDA accepted an abbreviated new drug application for Sandoz ANDA.

Originally approved for PAH, drug shows promise for CTEPH.

1 in 3 patients who get the condition in the hospital will die there.

Dysfunctional breathing had strong connections to poor asthma control.

Simvastatin may reduce inflammation, fibrosis, bronchial constriction, mucus